Tabalumab (Rheumatoid Arthritis) Forecast and Market Analysis

Tabalumab (Rheumatoid Arthritis) Forecast and Market Analysis

GlobalData has released its new PharmaPoint Drug Evaluation report, Tabalumab (Rheumatoid Arthritis) Forecast and Market Analysis. The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizer's Xeljanz (tofacitinib) and novel oral therapies awaiting approval such as: Eli Lilly's anti-BAFF, tabalumab and JAK1,2 inhibitor, baricitinib, and Rigel/AZ's SYK inhibitor, fostamatinib. These compounds will challenge the current biologics in the attempt to dislodge the stronghold of the TNF inhibitors, if their safety and efficacy profiles are proven once they enter the market.

 

Eli Lilly and Company's tabalumab is poised to become the first anti-BAFF mAb for the treatment of RA. Tabalumab binds and inhibits the activity of soluble and cell surface-bound BAFF which then decreases the activity, proliferation, and survival of B cells. It reduces levels of B cells responsible for autoantibody production in RA without obliterating the body's ability to generate immunoglobulins. Tabalumab is currently in Phase III in the US and EU and in Phase I in Japan.

To purchase and know more about this market research reports please visit: http://www.marketresearchreports.com/globaldata/tabalumab-rheumatoid-arthritis-forecast-and-market-analysis 

 

Scope

• Overview of RA, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
• Detailed information on Tabalumab including product description, safety and efficacy profiles as well as a SWOT analysis.
• Sales forecast for Tabalumab for the top eight countries from 2011 to 2022.
• Sales information covered for the US, France, Germany, the UK, Italy, Spain, Japan and Australia.

 

Reasons to buy

• Understand and capitalize by identifying products that are most likely to ensure a robust return
• Stay ahead of the competition by understanding the changing competitive landscape for rheumatoid arthritis.
• Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
• Make more informed business decisions from insightful and in-depth analysis of Tabalumab performance 
• Obtain sales forecast for Tabalumab from 2011 to 2022 in (the US, France, Germany, the UK, Italy, Spain, Japan and Australia)